Erratum

Off-label use of recombinant activated Factor VII (rFVIIa) for bleeding following a percutaneous liver biopsy

E. Gloster, M. Ilario, J. De Luna, T. DiMaio, R. Howard, R.-I. Bayer, A. Braverman & R. Strauss

Off-label use of recombinant activated Factor VII (rFVIIa) for massive bleeding in trauma and surgery

E. Gloster, P. O'Neill, T. DiMaio, D. Essex, M. Bluth, C. Catanese & R. Strauss

Vox Sanguinis 2002; 83 (supplement 2): 58–59 (abstracts)
In these two abstracts which appeared in the supplement issue to Vox Sanguinis mentioned above, the following error occurred: the wrong units were used in the Results section of each abstract. The correct text should read:

Off-label use of recombinant activated Factor VII (rFVIIa) for bleeding following a percutaneous liver biopsy
Results: One 30–40 µg/kg (6·6 ml) dose of rFVIIa resulted in prompt cessation of oozing. She continued to deteriorate, but required only one more RBC unit before death, a week after admission.

Off-label use of recombinant activated Factor VII (rFVIIa) for massive bleeding in trauma and surgery
Results: From July 2000 to December 2001 at KCHC, the six non-hemophiliac patients below were treated off-label with one or two 80–100 µg/kg doses of rFVIIa, for life-threatening coagulopathic bleeding refractory to standard component therapy.